Background
==========

*Klebsiella pneumoniae*, an important nosocomial pathogen, causes a wide range of infections including pneumonia, bacteremia, urinary tract infection, and sometimes even life-threatening septic shock \[[@B1]\]. The emergence of multi-drug resistant *K. pneumoniae*has reduced the efficacy of antibiotic treatments and prompted the reevaluation of previously but not currently applied antibiotics \[[@B2],[@B3]\] or a combined therapy \[[@B4]\]. Polymyxins, originally isolated from *Bacillus polymyxa*, have emerged as promising candidates for the treatment of infections \[[@B5]\]. As a member of antimicrobial peptides (APs), the bactericidal agent exerts its effects by interacting with the lipopolysaccharide (LPS) of gram-negative bacteria. The polycationic peptide ring on polymyxin competes for and substitutes the calcium and magnesium bridges that stabilize LPS, thus disrupting the integrity of the outer membrane leading to cell death \[[@B5],[@B6]\].

The *Klebsiella*capsular polysaccharide (CPS), which enabled the organism to escape from complement-mediated serum killing and phagocytosis \[[@B7],[@B8]\], has been shown to physically hinder the binding of C3 complement \[[@B9]\] or polymyxin B \[[@B10]\]. The assembly and transport of *Klebsiella*CPS followed the *E. coli*Wzy-dependent pathway \[[@B11]\], in which mutations at *wza*encoding the translocon protein forming the complex responsible for CPS polymer translocation and export resulted in an inability to assemble a capsular layer on the cell surface \[[@B12]\]. The CPS biosynthesis in *K. pneumoniae*was transcriptionally regulated by the two-component system (2CS) RcsBCD \[[@B13]\] where the deletion of the response regulator encoding gene *rcsB*in *K. pneumoniae*caused a loss of mucoid phenotype and reduction in CPS production \[[@B14]\].

In *Escherichia coli*and *Salmonella enterica*serovar Typhimurium, polymyxin B resistance is achieved mainly through the expression of LPS modification enzymes, including PmrC, an aminotransferase for the decoration of the LPS with phosphoethanolamine \[[@B15]\] and the *pmrHFIJKLM*operon \[[@B16],[@B17]\] (also called *pbgP*or *arn*operon \[[@B18],[@B19]\]) encoding enzymes. Mutations at *pmrF*, which encoded a transferase for the addition of 4-aminoarabinose on bactoprenol phosphate, rendered *S. enterica*and *Yersinia pseudotuberculosis*more susceptible to polymyxin B \[[@B16],[@B20]\]. The *S. enterica ugd*gene encodes an enzyme responsible for the supply of the amino sugar precursor ~L~-aminoarabinose for LPS modifications and hence the Ugd activity is essential for the resistance to polymyxin B \[[@B21]\]. On the other hand, the *E. coli ugd*mutant with an impaired capsule also became highly susceptible to polymyxin B \[[@B22]\].

The 2CS PmrA/PmrB, consisting of the response regulator PmrA and its cognate sensor kinase PmrB, has been identified as a major regulatory system in polymyxin B resistance \[[@B23],[@B24]\]. The resistance in *S. enterica*or *E. coli*has been shown to be inducible by the extracellular iron \[[@B25]\]. In addition to acidic pH \[[@B26]\], the role of ferric ions as a triggering signal for the expression of PmrA/PmrB has been demonstrated \[[@B23]\]. The 2CS PhoP/PhoQ which regulates the magnesium regulon \[[@B27]\] could also activate polymyxin B resistance under low magnesium in *S. enterica*, in which the PhoP/PhoPQ-dependent control is connected by the small basic protein PmrD. The expression of *pmrD*could be activated by PhoP while repressed by PmrA forming a feedback loop \[[@B28],[@B29]\]. The activated PmrD could then bind to the phosphorylated PmrA leading to a persistent expression of the PmrA-activated genes \[[@B30]\].

The PmrD encoding gene was also identified in *E. coli*and *K. pneumoniae*. However, *pmrD*deletion in *E. coli*had no effect on the bacterial susceptibility to polymyxin B \[[@B25]\]. Recently, the PhoP-dependent expression of *pmrD*has also been demonstrated in *K. pneumoniae*. According to the predicted semi-conserved PhoP box in the *pmrD*upstream region, a direct binding of PhoP to the *pmrD*promoter for the regulation was speculated \[[@B31]\].

In this study, specific deletions of genetic loci involved in CPS biosynthesis and LPS modifications were introduced into *K. pneumoniae*CG43, a highly virulent clinical isolate of K2 serotype \[[@B32]\]. Involvement of the genetic determinants in polymyxin B resistance was investigated.

Methods
=======

Plasmids, bacterial strains, and growth conditions
--------------------------------------------------

Bacterial strains and plasmids used in this study are listed in Table [1](#T1){ref-type="table"}, and the primers used are listed in Table [2](#T2){ref-type="table"}. *E. coli*, *K. pneumoniae*CG43 \[[@B32],[@B33]\] and its derivatives were propagated at 37°C in Luria-Bertani (LB) broth or M9 minimal medium. Bacterial growth was assessed by OD~600~. The antibiotics used include ampicillin (100 μg/ml), chloramphenicol (35 μg/ml), kanamycin (25 μg/ml), tetracycline (12.5 μg/ml) and streptomycin (500 μg/ml). Polymyxin B sulfate salt (Sigma-Aldrich) was prepared as 1 unit/μl stock solution in PBS and stored at 4°C before use.

###### 

Bacterial strains and plasmids used in this study

  Strain or plasmid      Description                                                                                                                      Reference or source
  ---------------------- -------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Strains                                                                                                                                                 
   *K. pneumponiae*                                                                                                                                       
    CG43S3               CG43 Sm^r^                                                                                                                       \[[@B14]\]
    Δ*pmrF*              CG43S3Δ*pmrF*Sm^r^                                                                                                               This study
    Δ*phoP*              CG43S3Δ*phoP*Sm^r^                                                                                                               This study
    Δ*pmrD*              CG43S3Δ*pmrD*Sm^r^                                                                                                               This study
    Δ*pmrA*              CG43S3Δ*pmrA*Sm^r^                                                                                                               This study
    Δ*ugd*               CG43S3Δ*ugd*Sm^r^                                                                                                                This study
    Δ*wza*               CG43S3Δ*wza*Sm^r^                                                                                                                This study
    Δ*lacZ*              CG43S3Δ*lacZ*Sm^r^                                                                                                               \[[@B35]\]
    Δ*lacZ*Δ*phoP*       CG43S3Δ*lacZ*Δ*phoP*Sm^r^                                                                                                        This study
    Δ*lacZ*Δ*pmrD*       CG43S3Δ*lacZ*Δ*pmrD*Sm^r^                                                                                                        This study
    Δ*lacZ*Δ*pmrA*       CG43S3Δ*lacZ*Δ*pmrA*Sm^r^                                                                                                        This study
    Δ*pmrA*Δ*phoP*       CG43S3Δ*pmrA*Δ*phoP*Sm^r^                                                                                                        This study
    Δ*rcsB*(B2202)       CG43S3Δ*rcsB*Sm^r^                                                                                                               \[[@B14]\]
    Δ*pmrA*Δ*rcsB*       CG43S3Δ*pmrA*Δ*rcsB*Sm^r^                                                                                                        This study
    Δ*pmrD*Δ*rcsB*       CG43S3Δ*pmrD*Δ*rcsB*Sm^r^                                                                                                        This study
    Δ*phoP*Δ*rcsB*       CG43S3Δ*phoP*Δ*rcsB*Sm^r^                                                                                                        This study
                                                                                                                                                          
   *E. coli*                                                                                                                                              
    S17-1λ*pir*          *hsdR recA pro*RP4-2 (Tc::Mu; Km::Tn*7*)(λ*pir*)                                                                                 \[[@B34]\]
    XL1-Blue MRF\' Kan   Δ(*mcrA*)*183*Δ(*mcrCB-hsdSMR-mrr*)*173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac*\[F\' *proAB lacI*^q^Z Δ*M15*Tn*5*(Kan^r^)\]   Stratagene
    BL21(DE3)            F^-^*ompT hsdS~B~(r~B~^-^m~B~^-^) gal dcm trxB*15::*kan*(DE3)                                                                    Novagen
                                                                                                                                                          
  Plasmids                                                                                                                                                
    yT&A                 T/A-type PCR cloning vector, Ap^r^                                                                                               Yeastern
    pET30b               His-tagged protein expression vector, Km^r^                                                                                      Novagen
    pBT                  Bait plasmid, *p15A*origin of replication, *lac-UV5*promoter, λ-cI open reading frame, Cm^r^                                     Stratagene
    pTRG                 Target plasmid, *ColE1*origin of replication, *lac-UV5*promoter, *RNAP*αopen reading frame, Tc^r^,                               Stratagene
    pBT-LGF2             Control plasmid containing a fragment encoding the yeast transcriptional activator Gal4 fused with λ-cI, Cm^r^                   Stratagene
    pTRG-GAL11^P^        Control plasmid containing a fragment encoding a mutant form of Gal11 protein, called Gal11P, fused with RNAPα, Tc^r^            Stratagene
    pKAS46               Suicide vector, *rpsL*, Ap^r^, Km^r^                                                                                             \[[@B34]\]
    pRK415               Shuttle vector, *mob*^+^, Tc^r^                                                                                                  \[[@B36]\]
    placZ15              promoter selection vector, *lacZ*^+^, Cm^r^                                                                                      \[[@B35]\]
    pRK415-PmrF          1.3-kb fragment containing a *pmrF*allele cloned into pRK415, Tc^r^                                                              This study
    pRK415-RcsB          1.2-kb fragment containing the entire rcsB locus cloned into pRK415, Tc^r^                                                       \[[@B39]\]
    pRK415-PmrA          1.1-kb fragment containing a *pmrA*allele cloned into pRK415, Tc^r^                                                              This study
    pRK415-PhoP          900-bp fragment containing a *phoP*allele cloned into pRK415, Tc^r^                                                              This study
    pRK415-PmrD          550-bp fragment containing a *pmrD*allele cloned into pRK415, Tc^r^                                                              This study
    placZ15-PpmrH        500-bp fragment containing the upstream region of the *K. pneumoniae pbgP*genes cloned into placZ15, Cm^r^                       This study
    placZ15-PpmrD        350-bp fragment containing the upstream region of the *K. pneumoniae pmrD*genes cloned into placZ15, Cm^r^                       This study
    pET30b-PhoP          711-bp fragment encoding full-length PhoP cloned into pET30b, Km^r^                                                              This study
    pET30b-PhoPN         447-bp fragment encoding residues 1-149 of PhoP cloned into pET30b, Km^r^                                                        This study
    pET30b-PmrBC         828-bp fragment encoding residues 90-365 of PmrB cloned into pET30b, Km^r^                                                       This study
    pET-PmrA             669-bp fragment encoding full-length PmrA cloned into pET29b, Km^r^                                                              This study
    pET-PmrD             243-bp fragment encoding full-length PmrD cloned into pET29b, Km^r^                                                              This study
    pBT-PmrA             669-bp fragment encoding full-length RcsB cloned into pBT, Cm^r^                                                                 This study
    pTRG-PmrD            243-bp fragment encoding full-length RcsA cloned into pTRG, Tc^r^                                                                This study

###### 

Oligonucleotide primers used in this study

  Primer     **Sequence**^**a**^                                Enzyme cleaved   Complementary position
  ---------- -------------------------------------------------- ---------------- -----------------------------------------
  ppmrF01    5\'-GATGGAAAAGCTGAAGGCGATGG-3\'                    None             -161 relative to the *pmrF*start codon
  ppmrF02    5\'-CAGC**GATATC**ATACCCGGCGTC-3\'                 *Eco*RV          +1116 relative to the *pmrF*start codon
  pmrA06     5\'-GAG**CCATGG**TCTATTCCGTG-3\'                   *Nco*I           +682 relative to the *pmrA*start codon
  pmrAp03    5\'-CAATT**GGATCC**AGGGCTGTAC-3\'                  *Bam*HI          -424 relative to the *pmrA*start codon
  phoP01     5\'-CGCTCGCCGTTC**GGATCC**TG-3\'                   *Bam*HI          -171 relative to the *phoP*start codon
  phoP02     5\'-GCAAC**GGTACC**TTCATCAGCGC-3\'                 *Kpn*I           +729 relative to the *phoP*start codon
  pmrDe02    5\'-C**GAGCTC**GTGTTATTTGTCGGCGTTTGTC-3\'          *Sac*I           +250 relative to the *pmrD*start codon
  pmrDp01    5\'-T**GGATCC**TTCATGACGCTCTCTC-3\'                *Bam*HI          -278 relative to the *pmrD*start codon
  pmrDp02    5\'-CGCAC**AGATCT**GAAGCACGAC-3\'                  *Bgl*II          +75 relative to the *pmrD*start codon
  pmrHp01    5\'-TCT**GGATCC**TGGTCATTAATTGCCCGGC-3\'           *Bam*HI          -425 relative to the *pmrH*start codon
  pmrHp02    5\'-CTT**AGATCT**CGCTCATCATCATCCTGTTC-3\'          *Bgl*II          +34 relative to the *pmrH*start codon
  phoP05     5\'-GTAATGACAGCGGGAAGATATG-3\'                     None             +753 relative to the *phoP*start codon
  phoP06     5\'-CAGCCGTTTATATTTTGCGT-3\'                       None             -25 relative to the *phoP*start codon
  pmrBe03    5\'-T**GGATCC**TCGCAAGATCACCCGCC-3\'               *Bam*HI          +283 relative to the *pmrB*start codon
  pmrBe04    5\'-C**AAGCTT**ATGGGTGCTGACGTTCTGAC-3\'            *Hin*dIII        +1095 relative to the *pmrB*start codon
  KP1760-1   5\'-GGAATTC**CATATG**AAAATCTTAGTCATTGAA-3\'        *Nde*I           +1 relative to the *pmrA*start codon
  KP1760-2   5\'-CCG**CTCGAG**CTATTCCGTGTCGATGTTGTT-3\'         *Xho*I           +672 relative to the *pmrA*start codon
  KP3573-1   5\'-GGAATTC**CATATG**GAGTGGTGGGTAAAAAAA-3\'        *Nde*I           +1 relative to the *pmrD*start codon
  KP3573-2   5\'-CCG**CTCGAG**TTTGTCGGCGTTTGTCCAACG-3\'         *Xho*I           +243 relative to the *pmrD*start codon
  pmrA10     5\'-A**CTCGAG**CCATGGTCTATTCCGTG-3\'               *Xho*I           +1 relative to the *pmrA*start codon
  pmrA11     5\'-AAT**GCGGCCGC**AATGAAAATCTTAGTC-3\'            *Not*I           +672 relative to the *pmrA*start codon
  pmrDe15    5\'-AAA**GCGGCCGC**GATGGAGTGGTGGGTAAAAAAAGTA-3\'   *Not*I           +1 relative to the *pmrD*start codon
  pmrDe16    5\'-TTT**CTCGAG**TGTGTTATTTGCCGGCGTTT-3\'          *Xho*I           +243 relative to the *pmrD*start codon

^a^The nucleotide sequence recognized by each restriction enzyme listed are in bold text.

Construction of specific gene-deletion mutants
----------------------------------------------

Specific gene deletion was individually introduced into the chromosome of *K. pneumoniae*CG43S3 by allelic exchange strategy \[[@B14]\]. In brief, two approximately 1000-bp DNA fragments flanking both sides of the deleted region were cloned into the suicide vector pKAS46 \[[@B34]\]. The resulting plasmid was then mobilized from *E. coli*S17-1 λ*pir*\[[@B34]\] to *K. pneumoniae*CG43S3, *K. pneumoniae*CG43S3Δ*lacZ*\[[@B35]\], or *K. pneumoniae*CG43S3Δ*rcsB*\[[@B14]\], by conjugation. The transconjugants were selected with ampicillin and kanamycin on M9 agar plates. Colonies were grown overnight in LB broth at 37°C and then spread onto an LB agar plate containing 500 μg/ml of streptomycin. The streptomycin-resistant and kanamycin-sensitive colonies were selected, and the deletion was verified by PCR and Southern analysis using gene-specific probe. The resulting *K. pneumoniae*mutants are listed Table [1](#T1){ref-type="table"}.

To obtain the complementation plasmids, DNA fragments containing the coding sequence of *pmrA*, *phoP*, *pmrF*, or *pmrD*were PCR-amplified with primer sets pmrAp03/pmrA06, phoP01/phoP02, ppmrF01/ppmrF02 or pmrDp01/pmrDe02 (Table [2](#T2){ref-type="table"}) and cloned into the shuttle vector pRK415 \[[@B36]\] to generate pRK415-PmrA, pRK415-PhoP, pRK415-PmrF and pRK415-PmrD (Table [1](#T1){ref-type="table"}), respectively.

Extraction and quantification of CPS
------------------------------------

Bacterial CPS was extracted using the method described \[[@B37]\]. Briefly, 500 μl of overnight culture was mixed with 100 μl of 1% Zwittergent 3-14 (Sigma-Aldrich) in 100 mM citric acid (pH 2.0) and incubated at 50°C for 20 min. After centrifugation, 250 μl of the supernatant was used to precipitate CPS with 1 ml of absolute ethanol. The pellet was dissolved in 200 μl distilled water, and then 1,200 μl of 12.5 mM borax in H~2~SO~4~was added. The mixture was vigorously mixed, boiled for 5 min, cooled, and then 20 μl 0.15% 3-hydroxydiphenol (Sigma-Aldrich) was added. OD~520~was measured and the uronic acid content was determined from a standard curve of glucuronic acid and expressed as μg per 10^9^CFU.

Polymyxin B resistance assay
----------------------------

Polymyxin B resistance assay was performed essentially as described \[[@B10]\] with some modifications. In brief, the overnight-grown *K. pneumoniae*strains were washed twice with saline (0.85% NaCl solution, w/v) and subcultured in LB broth alone or supplemented with 1 mM FeCl~3~or with 10 mM MgCl~2~at 37°C. The log-phased (OD~600~of 0.7) bacterial culture was then washed twice and a suspension containing ca. 2.5 × 10^4^CFU/ml in LB was prepared. Then, 100 μl of the suspension was placed in each well of a 96-well micro-titer plate and 100 μl PBS or PBS-diluted polymyxin B was added to each well to final concentrations of 0, 1, 2, or 4 units/ml of polymyxin B. The plate was incubated at 37°C for 1 h with shaking. Subsequently, 100 μl of the suspension was directly plated on LB agar plates and incubated at 37°C overnight to determine the number of viable bacteria. The survival rates were expressed as colony counts divided by the number of the same culture treated with PBS and multiplied by 100. The assays were performed thrice, and the results were shown as the average ± standard deviation from triplicate samples. The survival rates at 1 and 2 units/ml (Figure [1C](#F1){ref-type="fig"}) and at 2 units (Figure [2A](#F2){ref-type="fig"} and Figure [3AB](#F3){ref-type="fig"}) of polymyxin B were shown.

![**Deletion effects of *ugd*, *wza*and *rcsB*genes on *Klebsiella*CPS production and resistance to polymyxin B**. **(A)**Comparison of colony morphology. The *K. pneumoniae*strains were streaked on an LB agar plate, incubated at 37°C overnight and photographed. **(B)**Sedimentation test. The strains were cultured overnight in LB broth at 37°C and subjected to centrifugation at 4,000 ×*g*for 5 min. Quantification of K2 CPS amounts of each strain is shown below the figure. Values are shown as averages ± standard deviations from triplicate samples. **(C)**Polymyxin resistance assay. The log-phased cultures of *K. pneumoniae*CG43S3, Δ*ugd*, Δ*wza*or Δ*rcsB*mutants were challenged with 1 or 2 units/ml of polymyxin B. **(D)**Polymyxin resistance assay. The log-phased culture of *K. pneumoniae*strains were challenged with 2 or 4 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. \*, *P*\< 0.01 compared to the parental strain CG43S3. \*\*, *P*\< 0.01 compared to each strain carrying pRK415.](1423-0127-17-60-1){#F1}

![**Involvement of *K. pneumoniae pmrF*gene in polymyxin B resistance and intramacrophage survival**. **(A)**The log-phased cultures of *K. pneumoniae*CG43S3, the Δ*pmrF*mutant or Δ*pmrF*carrying pRK415-PmrF were grown in LB or LB supplemented with 1 mM Fe^3+^and then challenged with 2 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. **(B)**The survival rates of *K. pneumoniae*CG43S3Δ*rcsB*, the isogenic Δ*pmrF*Δ*rcsB*mutant, and Δ*pmrF*Δ*rcsB*mutant strain carrying the complementation plasmid pRK415-PmrF within the mouse macrophage RAW264.7 were determined. The results shown are relative survival rates which were calculated from the viable colony counts of intracellular bacteria divided by individual original inoculums. Values are shown as the average of five replicas. Error bars, standard deviations. \*, *P*\< 0.01 compared to each parental strain; \*\*, *P*\< 0.01 compared to each mutant strain carrying pRK415-PmrF.](1423-0127-17-60-2){#F2}

![**Effects of *K. pneumoniae pmrA, pmrD*and *phoP*deletion and complementation in polymyxin B resistance and intramacrophage survival**. **(A)**The log-phased cultures of *K. pneumoniae*CG43S3, the Δ*pmrA*, Δ*pmrD*or Δ*phoP*mutants were grown in LB, LB supplemented with 10 mM Mg^2+^or LB supplemented with 1 mM Fe^3+^and then challenged with 2 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. **(B)**The log-phased cultures of *K. pneumoniae*CG43S3 carrying pRK415, the Δ*pmrA*Δ*phoP*mutant strains carrying pRK415, pRK415-PhoP or pRK415-PmrA were grown in LB and challenged with 2 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. **(C)**The survival rates of *K. pneumoniae*CG43S3Δ*rcsB*, the isogenic Δ*pmrA*Δ*rcsB*, Δ*phoP*Δ*rcsB*and Δ*pmrD*Δ*rcsB*mutants, and each mutant strain carrying the complementation plasmids pRK415-PmrA, pRK415-PhoP or pRK415-PmrD within the mouse macrophage RAW264.7 were determined. The results shown are relative survival rates which were calculated from the viable colony counts of intracellular bacteria divided by individual original inoculums. Values are shown as the average of five replicas. Error bars, standard deviations. \*, *P*\< 0.01 compared to each parental strain; \*\*, *P*\< 0.01 compared to each mutant strain carrying the complementation plasmid.](1423-0127-17-60-3){#F3}

Cell line, cell culture and phagocytosis assay
----------------------------------------------

The mouse macrophage cell line RAW264.7 was cultivated in Dulbecco\'s Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (Gibco), 100 units/ml of penicillin and 100 μg/ml of streptomycin (Gibco) at 37°C under 5% CO~2~. The evaluation of bacterial phagocytosis was carried out as described with some modifications \[[@B9]\]. In brief, cells were washed, resuspended in DMEM containing 10% FBS, and approximately 10^6^cells per well were seeded in a 24 well tissue culture plate and incubated at 37°C for 16 h. Then 100 μl of the bacterial suspension (approximately 3 × 10^8^CFU/ml in PBS) was used to infect each well to obtain a ratio of ca. 30 bacteria per macrophage. After incubation for 2 h, the cells were washed thrice, then 1 ml of DMEM containing 100 μg/ml of gentamycin was added and incubated for another 2 h to kill the extracellular bacteria. Cells were washed thrice, 1 ml of 0.1% Triton X-100 was added and incubated at room temperature for 10 min with gentle shaking to disrupt the cell membrane. The cell lysate was diluted serially with PBS, plated onto LB agar plates and incubated overnight for determining viable bacteria count. The relative survival rates after phagocytosis were expressed as the colony counts of viable bacteria divided by those of the original inoculums and multiplied by 100. Three independent trials were performed, and the data shown were the average ± standard deviation from five replicas.

Construction of reporter fusion plasmid and measurement of promoter activity
----------------------------------------------------------------------------

The approximately 350 or 500-bp DNA fragments containing the upstream region of the *K. pneumoniae pmrD*or *pmrHFIJKLM*gene cluster were PCR-amplified with primers pmrDp01/pmrDp02 or pmrHp01/pmrHp02 (Table [2](#T2){ref-type="table"}), respectively and cloned in front of a promoter-less *lacZ*gene of the promoter selection plasmid placZ15 \[[@B35]\]. The resulting plasmids, placZ15-PpmrD and placZ15-PpmrH were mobilized from *E. coli*S17-1 λ*pir*to *K. pneumoniae*strains by conjugation. β-galactosidase activity was determined as previously described \[[@B35]\]. In brief, overnight cultures were washed twice with saline and subcultured in LB alone or supplemented with 10 mM MgCl~2~, 0.1 mM FeCl~3~, or 0.1 mM FeCl~3~plus 0.3 mM ferric iron scavenger deferoxamine (Sigma-Aldrich) to mid-log phase (OD~600~of 0.7). Then 100 μl of the culture was mixed with 900 μl of Z buffer (60 mM Na~2~HPO~4~, 40 mM NaH~2~PO~4~, 10 mM KCl, 1 mM MgSO~4~, 50 mM β-mercaptoethanol), 17 μl of 0.1% SDS, and 35 μl of chloroform and the mixture was shaken vigorously. After incubation at 30°C for 10 min, 200 μl of 4 mg/ml ONPG (o-nitrophenyl-β-D-galactopyranoside) (Sigma-Aldrich) was added. Upon the appearance of yellow color, the reaction was stopped by adding 500 μl 1 M Na~2~CO~3~. OD~420~was recorded and the β-galactosidase activity was expressed as Miller units \[[@B38]\]. Each sample was assayed in triplicate, and at least three independent experiments were carried out. The data shown were calculated from one representative experiment and shown as the means and standard deviation from triplicate samples.

Cloning, expression and purification of recombinant proteins
------------------------------------------------------------

The DNA fragment of PhoP coding region was PCR amplified from the genomic DNA of *K. pneumoniae*CG43S3 with primers phoP05/phoP06 (Table [2](#T2){ref-type="table"}). The amplified PCR products were cloned into the PCR cloning vector yT&A (Yeastern Biotech, Taiwan). The *Eco*RI/*Bam*HI and *Sal*I fragments from the resulting plasmid were then cloned individually into pET30b (Novagen, Madison, Wis) to generate pET30b-PhoP and pET30b-PhoPN to allow the in-frame fusion to the N-terminal His codons. Plasmid pET30b-PmrBC was constructed by cloning DNA fragments PCR-amplified with pmrBe03/pmrBe04 (Table [2](#T2){ref-type="table"}) into a *Bam*HI/*Hin*dIII site on pET30b. Plasmids pET-PmrA and pET-PmrD (courtesy of Dr. Chinpan Chen, Academia Sinica, Taipei, Taiwan) were constructed by cloning DNA fragments PCR-amplified with KP1760-1/KP1760-2 and KP3573-1/KP3573-2 (Table [2](#T2){ref-type="table"}) into an *Nde*I/*Xho*I site, respectively into pET29b. The resulting plasmids were transformed into *E. coli*BL21(DE3) (Invitrogen, USA), and the recombinant proteins were over-expressed by induction with 0.5 mM isopropyl 1-thio-β-D-galactopyranoside (IPTG) for 3 h at 37°C. The proteins were then purified from total cell lysate by affinity chromatography using His-Bind resin (Novagen, Madison, Wis). After purification, the eluent was dialyzed against 1× protein storage buffer (10 mM Tris-HCl pH 7.5, 138 mM NaCl, 2.7 mM KCl, and 10% glycerol) at 4°C overnight, followed by condensation with PEG20000, and the purity was determined by SDS-PAGE analysis.

DNA electrophoretic mobility shift assay (EMSA)
-----------------------------------------------

EMSA was performed as previously described \[[@B14]\]. In brief, the DNA fragment encompassing the putative *pmrD*promoter region was obtained by PCR amplification and then end-labeled with \[γ-^32^P\]ATP by T4 polynucleotide kinase. The purified His-PhoP or His-PhoP~N149~protein was mixed with the DNA probe in a 50-μl reaction mixture containing 20 mM Tris-HCl pH 8.0, 50 mM KCl, 1 mM MgCl~2~, 1 mM dithiothreitol, and 7.5 mM acetyl phosphate. The mixture was incubated at room temperature for 30 min, mixed with 0.1 volume of DNA loading dye, and then loaded onto a 5% nondenaturing polyacrylamide gel containing 5% glycerol in 0.5× TBE buffer (45 mM Tris-HCl pH 8.0, 45 mM boric acid, 1.0 mM EDTA). After electrophoresis at a constant current of 20 mA at 4°C, the result was detected by autoradiography.

Bacterial two-hybrid assay
--------------------------

The bacterial two-hybrid assay was performed as described previously \[[@B20],[@B30]\]. The DNA fragments encoding full-length PmrA and PmrD were PCR-amplified with primer pairs pmrA10/pmrA11 and pmrDe15/pmrDe16 (Table [2](#T2){ref-type="table"}) respectively, and cloned into the 3\' end of genes encoding the α subunit of RNA polymerase (RNAPα) domain on pBT and λ-cI repressor protein domain on pTRG. The resulting RNAPα-PmrA and λ-cI-PmrD encoding plasmids, pBT-PmrA and pTRG-PmrD, were confirmed by DNA sequencing. The positive control plasmids used were pTRG-Gal11^P^and pBT-LGF2 (Stratagene). The pBT and pTRG derived plasmids were co-transformed into *E. coli*XL1-Blue MRF\' Kan cells and selected on LB agar plates supplemented with 12.5 μg/ml tetracycline, 25 μg/ml chloramphenicol, and 50 μg/ml kanamycin. To investigate the protein-protein interaction *in vivo*, cells were grown until the OD~600~reached 0.3 and then diluted serially (10^-1^, 10^-2^, 10^-3^, and 10^-4^order). Two-microliters of the bacterial culture were spotted onto LB agar plates supplemented with 350 μg/ml carbenicillin, 25 μg/ml chloramphenicol, 50 μg/ml kanamycin, 12.5 μg/ml tetracycline, 50 μg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside), and 20 μM IPTG. Growth of the bacterial cells was observed after incubation at 30°C for 36 h.

*In vitro*phosphotransfer assay
-------------------------------

The *in vitro*phosphotransfer assay was performed essentially as described \[[@B30]\]. The phospho-PmrB~C276~protein was obtained by pre-incubation of His-PmrB~C276~protein (5 μM) with 40 μCi of \[γ-32P\]ATP in 80 μl of 1× phosphorylation buffer (10 mM Tris-HCl, pH 7.5; 138 mM NaCl; 2.7 mM KCl; 1 mM MgCl~2~; 1 mM DTT) for 1 h at room temperature. The reaction mixture was then chilled on ice, and 5 μl of the mixture was removed and mixed with 2.5 μl of 5× SDS sample buffer as a reference sample. The phospho-PmrB~C276~protein mixture (30 μl) was then mixed with equal volumes of 1× phosphorylation buffer containing either PmrA (10 μM) or PmrA with PmrD (each at 10 μM) to initiate the phosphotransfer reaction. A 10-μl aliquot was removed at specific time points, mixed with 2.5 μl of 5× SDS sample buffer to stop the reaction, and the samples were kept on ice until the performance of SDS-PAGE. After electrophoresis at 4°C, the signal was detected by autoradiography.

Kinase/phosphatase and autokinase assay
---------------------------------------

The assays were performed essentially as described \[[@B30]\]. The recombinant protein His-PmrB~C276~(2.5 μM) was incubated with His-PmrA (5 μM) alone or with His-PmrD (5 μM) for kinase/phosphatase assay or incubated with His-PmrD (5 μM) alone for autokinase assay. The reactions were carried out in 30 μl of 1× phosphorylation buffer with 3.75 μCi \[γ-^32^P\]ATP at room temperature and started with the addition of His-PmrB~C276~. An aliquot of 10-μl was removed at specific time points, mixed with 5× SDS sample buffer to stop the reaction, and the samples were kept on ice until the performance of SDS-PAGE. After electrophoresis at 4°C, the signal was detected by autoradiography.

Statistical analysis
--------------------

Student\'s *t*test was used to determine the significance of the differences between the CPS amounts and the levels of β-galactosidase activity. *P*values less than 0.01 were considered statistically significant.

Results
=======

Reduced production of capsular polysaccharide had minor effect on polymyxin B resistance in *K. pneumoniae*
-----------------------------------------------------------------------------------------------------------

*K. pneumoniae*CG43 is a highly encapsulated virulent strain \[[@B32]\]. In order to verify the role of CPS in polymyxin B resistance, the Δ*ugd*and Δ*wza*mutants were generated by allelic exchange strategy, and their phenotype as well as the amount of CPS produced were compared with the parental strain CG43S3 and Δ*rcsB*mutant \[[@B14]\]. As shown in Figure [1A](#F1){ref-type="fig"}, the Δ*ugd*and Δ*wza*mutants formed apparently smaller colonies on LB agar plate compared with the glistering colony of the parental strain CG43S3. Although the colony morphology of the Δ*rcsB*mutant was indistinguishable from CG43S3, the CPS-deficient phenotype was evident as assessed using sedimentation assay and the amount of K2 CPS produced (Figure [1B](#F1){ref-type="fig"}). Deletion of *rcsB*resulted in an approximately 50% reduction of the CPS, while the Δ*wza*mutant produced less than 20% of that of its parental strain CG43S3. The CPS biosynthesis in Δ*ugd*mutant was almost abolished, indicating an indispensible role of Ugd in CPS biosynthesis. To investigate how the CPS level was associated with polymyxin B resistance, the survival rates of the strains challenged with polymyxin B were compared. The Δ*ugd*mutant producing the lowest amount of CPS was extremely sensitive to the treatment of polymyxin B (Figure [1C](#F1){ref-type="fig"}). Although the Δ*ugd*mutant was CPS-deficient, the impaired polymyxin resistance may have been largely attributed to the defect in LPS biosynthesis since the survival rates of Δ*wza*and Δ*rcsB*mutants appeared to be comparable with the parental strain CG43S3. This argues against the notion that the level of polymyxin B resistance is positively correlated to the amount of CPS \[[@B10]\]. Nevertheless, the possibility that a higher amount of CPS was required for the resistance could not be ruled out. As shown in Figure [1D](#F1){ref-type="fig"}, the introduction of pRK415-RcsB \[[@B39]\] resulted in a significantly higher resistance to polymyxin B in both Δ*rcsB*mutant and its parental strain. This indicated a protective effect of large amounts of CPS in polymyxin resistance.

PmrF is involved in polymyxin B resistance and survival within macrophage
-------------------------------------------------------------------------

To investigate if the *K. pneumoniae pmr*homologues played a role in polymyxin B resistance, a *pmrF*deletion mutant strain and a plasmid pRK415-PmrF were generated. As shown in Figure [2A](#F2){ref-type="fig"}, when the strains were grown in LB medium, a low magnesium condition \[[@B40]\], differences in the survival rates were not apparent. When the strains were grown in LB supplemented with 1 mM FeCl~3~, an apparent deleting effect of *pmrF*in polymyxin B resistance was observed, and the survival rate could be restored by the introduction of pRK415-PmrF. The results indicated a role of PmrF in the polymyxin B resistance in high iron condition.

In addition to the mucosa surfaces, antimicrobial peptides and proteins play important roles in the microbicidal activity of phagosome \[[@B41]\]. To investigate the effect of *pmrF*deletion in the bacterial survival within phagosome, phagocytosis assay was carried out. Since *K. pneumoniae*CG43S3 was highly resistant to engulfment by phagocytes in our initial experiments, the Δ*rcsB*mutant which produced less CPS was used as the parental strain to generate Δ*pmrF*Δ*rcsB*mutant. As shown in Figure [2B](#F2){ref-type="fig"}, deletion of *pmrF*resulted in an approximately four-fold reduction in the recovery rate, which was restored after the introduction of pRK415-PmrF. This indicated an important role of *pmrF*not only in polymyxin B resistance but also in bacterial survival within macrophage.

Deletion effect of *pmrA*, *pmrD*or *phoP*on polymyxin B resistance in *K. pneumoniae*
--------------------------------------------------------------------------------------

To investigate how PmrA, PhoP and PmrD were involved in the regulation of polymyxin B resistance in *K. pneumoniae*, Δ*pmrA*, Δ*phoP*and Δ*pmrD*mutant strains were generated. Deletion of either one of these genes resulted in a dramatic reduction of resistance to polymyxin B when the strains were grown in LB medium (Figure [3A](#F3){ref-type="fig"}). The deleting effects were no longer observed when the strains grown in LB supplemented with 10 mM magnesium, implying an involvement of the PhoP-dependent regulation in LB, a low magnesium environment. Under high-iron conditions, the deletion of *pmrA*caused the greatest reduction in the survival rate. Introduction of pRK415-PmrA or pRK415-PhoP into the Δ*pmrA*Δ*phoP*double mutant strain not only restored but also enhanced the bacterial resistance to polymyxin B (Figure [3B](#F3){ref-type="fig"}), which is likely due to an over-expression level of *phoP*or *pmrA*by the multicopy plasmid. Finally, whether the deletion of *pmrA*, *phoP*or *pmrD*affected the survival rate in phagosomes was also investigated. Interestingly, deletion of *phoP*resulted in most apparent effect while the *pmrA*deletion had less effect on the bacterial survival in macrophages. This was probably due to low iron concentration in the phagosomes \[[@B40]\]. The introduction of pRK415-PhoP or pRK415-PmrD could restore the recovery rates of Δ*phoP*Δ*rcsB*and Δ*pmrD*Δ*rcsB*, although not to the extent displayed by the parental strain. Taken together, our results indicate the presence of two independent pathways in the regulation of polymyxin B resistance and the bacterial survival within macrophage phagosomes.

Effect of *pmrA*, *phoP*or *pmrD*deletion on P~*pmrH*~::*lacZ*or P~*pmrD*~::*lacZ*activity
------------------------------------------------------------------------------------------

As the functional role of the structural gene *pmrF*and the regulator genes *phoP*, *pmrD*and *pmrA*was verified, it would be of importance to investigate the regulatory network govern by PhoPQ-PmrD-PmrAB on the expression of *pmr*genes. Sequence analysis has revealed PhoP and PmrA box consensus in the upstream region of *pmrH*and PhoP box consensus in the upstream region of *pmrD*(Figure [4A](#F4){ref-type="fig"}). To investigate the interplay of PhoP, PmrA, and PmrD on the expression of *pmr*and *pmrD*genes, the reporter plasmids placZ15-PpmrH and placZ15-PpmrD were constructed and mobilized into *K. pneumoniae*CG43S3Δ*lacZ*and its derived Δ*pmrA*Δ*lacZ*, Δ*pmrD*Δ*lacZ*or Δ*phoP*Δ*lacZ*isogenic strains, respectively. The β-galactosidase activities of *K. pneumoniae*transformants under different environmental conditions were determined. In the wild-type strain CG43S3Δ*lacZ*, the P~*pmrH*~::*lacZ*activity was repressed in the presence of high magnesium but enhanced in high ferric ion (Figure [4B](#F4){ref-type="fig"}). Such iron-inducible activity was abolished after the addition of iron scavenger deferoxamine. As shown in Figure [4B](#F4){ref-type="fig"}, deleting effect of *pmrA*or *phoP*on the activity of P~*pmrH*~::*lacZ*could be observed in LB or LB supplemented with ferric iron. The negative effect of *pmrD*deletion was also apparent at high iron condition but was abolished after the addition of deferoxamine. The results clearly demonstrate the involvement of PmrA, PhoP and PmrD in the regulation of the expression of *pmr*genes, particularly in the presence of high ferric irons. As shown in Figure [4C](#F4){ref-type="fig"}, the P~*pmrD*~::*lacZ*activity was significantly reduced in high-magnesium conditions or upon the deletion of *phoP*. Interestingly, the deletion of *pmrA*or high ferric irons had little effect on the activity of P~*pmrD*~::*lacZ*. The results suggest that the expression of *K. pneumoniae pmrD*is regulated in a PhoP-dependent but PmrA-independent manner.

![**Schematic representation of *pmrH*and *pmrD*loci and determination of *K. pneumoniae*P~*pmrH*~::*lacZ*and P~*pmrD*~::*lacZ*activity**. **(A)**Diagrammatic representation of the *pmrH*and *pmrD*loci. The large arrows represent the open reading frames. The relative positions of the primer sets used in PCR-amplification of the DNA fragments encompassing the P~*pmrH*~and P~*pmrD*~regions are indicated, and the numbers denote the relative positions to the translational start site. The name and approximate size of the DNA probes used in electro-mobility shift assay (EMSA) are shown on the left. The dashed boxes indicate the predicted PhoP and PmrA binding sequences and the alignment result is shown below. The identical nucleotide sequences are underlined. HP, hypothetical protein. **(B)**The β-galactosidase activities of log-phased cultures of *K. pneumoniae*strains carrying placZ15-PpmrH grown in LB, LB containing 10 mM MgCl~2~, LB containing 0.1 mM FeCl~3~or 0.1 mM FeCl~3~plusing 0.3 mM deferoxamine were determined and expressed as Miller units. **(C)**The β-galactosidase activities of log-phased cultures of *K. pneumoniae*strains carrying placZ15-PpmrD grown in LB, LB containing 10 mM MgCl~2~or LB containing 0.1 mM FeCl~3~were determined and expressed as Miller units. The data shown were the average ± standard deviations from triplicate samples. \*, *P*\< 0.01 compared to the same strain grown in LB medium. \*\*, *P*\< 0.01 compared to the parental strain grown in LB medium. \#, *P*\< 0.01 compared to the parental strain grown in LB medium supplemented with ferric ions.](1423-0127-17-60-4){#F4}

Analysis of EMSA indicates a direct binding of the recombinant PhoP to ~*pmrD*~
-------------------------------------------------------------------------------

The binding of PhoP or PmrA to P~*pmrH*~has been determined recently \[[@B31]\]. In order to determine whether PhoP binds directly to P~*pmrD*~, EMSA was performed. As shown in Figure [5A](#F5){ref-type="fig"}, binding of the recombinant His-PhoP protein to P~*pmrD*~was evident by the formation of a protein/DNA complex with a slower mobility. The binding specificity was also examined by the addition of specific DNA competitor or non-specific DNA competitor. As shown in Figure [5B](#F5){ref-type="fig"}, the formation of protein/DNA complex diminished when His-PhoP~N149~, in which the carboxyl-terminal helix-turn-helix domain has been truncated, was used instead of His-PhoP. The results strongly suggest the PhoP binds via its C-terminal domain to the promoter of *pmrD*for the activation of the *pmrD*expression in *K. pneumoniae*.

![**Binding of His-PhoP and His-PhoP~N149~to P~*pmrD*~**. **(A)**Specific binding of recombinant His-PhoP protein to the putative *pmrD*promoter. EMSA was performed by using the ^32^P-labeled DNA probe of P~*pmrD*~incubated with increasing amounts of the His-PhoP (lanes 2 to 5), with 40 pmole of His-PhoP plus increasing amounts of the unlabeled P~*pmrD*~DNA (specific competitor, lane 6 to 9), or with excess amounts of non-specific competitor DNA (lane 10 and 11). The amounts of recombinant proteins and DNA probes used are indicated in the figure. **(B)**EMSA was performed with 0, 4 or 40 pmole of His-PhoP (lanes 1 to 3), His-PhoP~N149~(lanes 4 to 6) or 100 pmole of BSA (lane 7). The arrows indicate the PhoP/P~*pmrD*~complex and free probe of P~*pmrD*~.](1423-0127-17-60-5){#F5}

Two-hybrid analysis of the *in vivo*interaction between *Klebsiella*PmrD and PmrA
---------------------------------------------------------------------------------

The interaction between *Klebsiella*PmrD and PmrA has been shown as a prerequisite for the connector-mediated pathway \[[@B31]\]. To demonstrate *in vivo*interaction, a bacterial two-hybrid assay was performed. The plasmid pBT-PmrA carrying the RNAPα-PmrA coding region and the plasmid pTRG-PmrD carrying the λ-cI-PmrD coding sequence were generated. *In vivo*interaction between the two reporter strains allowed the binding of λ-cI to the operator region as well as the recruitment of α-RNAP for the expression of the *ampR*and *lacZ*reporter genes. The bacteria harboring the positive control plasmids pTRG-Gal11^P^/pBT-LGF2 showed a more vigorous growth on the indicator plate, as reflected by the apparent colony formation when the culture was diluted serially (Figure [6A](#F6){ref-type="fig"}). In contrast, the strain carrying the negative control vectors pBT/pTRG revealed impaired colony formation. As shown in Figure [6A](#F6){ref-type="fig"}, a similar growth pattern of the *E. coli*cells harboring pBT-PmrA/pTRG-PmrD to that of the positive control cells was observed indicating an interaction between the PmrD and PmrA.

![***Klebsiella*PmrD interacts with PmrA to prevent dephosphorylation**. **(A)**Bacterial two-hybrid analysis of PmrD/PmrA interaction *in vivo*. The *E. coli*XL1-Blue cells co-transformed with various combinations of pTRG and pBT-derived plasmids were diluted serially and spotted onto the indicator plate. The bacterial growth after 36 h was investigated and photographed. Combinations of plasmids carried by each strain were indicated above the figure. **(B)***Klebsiella*PmrD prevents the dephosphorylation of PmrA by its cognate sensor protein. The phosphorylation state of the recombinant His-PmrA protein was monitored upon the addition of the sensor protein His-PmrB~C276~in the presence (PmrD) or absence (-) of purified His-PmrD protein at specific time points as indicated. The arrows indicate phospho-PmrA (P-PmrA) and phospho-PmrB~C276~(P-PmrB~C276~). **(C)**Kinase/phosphatase assay was carried out using the recombinant His-PmrA (final concentration 5 μM) and His-PmrB~C276~(final concentration 2.5 μM) in the presence (PmrD) or absence (-) of the recombintant His-PmrD protein (final concentration 5 μM). The small cationic proteins RNase A and cytochrome C were introduced individually as a negative control at a final concentration of 5 μM. **(D)**Autokinase assay of the recombinant His-PmrB~C276~(final concentration 2.5 μM) was performed in the presence (PmrD) or absence (-) of the recombintant His-PmrD protein (final concentration 5 μM).](1423-0127-17-60-6){#F6}

The PmrD binds to PmrA to prevent dephosphorylation
---------------------------------------------------

In *S. enterica*, the phosphorylation of PmrA by the cognate sensor protein PmrB has been demonstrated to enhance its affinity in binding to its target promoter. The subsequent dephosphorylation of PmrA by PmrB helped to relieve from over-activation of this system (1). In *Salmonella*, PmrD has been shown to be able to protect PmrA from both intrinsic and PmrB-mediated dephosphorylation (22). To verify if *Klebsiella*PmrD also participates in the phosphorylation, *in vitro*phosphotransfer assay was carried out with the recombinant proteins His-PmrA, His-PmrD and His-PmrB~C276~. As shown in Figure [6B](#F6){ref-type="fig"}, the His-PmrA was rapidly phosphorylated upon addition of the autophosphorylated His-PmrB~C276~and then gradually dephosphorylated. Addition of His-PmrD apparently prolong the phosphorylation state of the His-PmrA, which could be maintained for at least 60 min (Figure [6B](#F6){ref-type="fig"}). The phosphorylated His-PmrA appeared to be very stable in the presence of the His-PmrD since the phosphorylation signal was still detectable 4 h later (data not shown). As shown in Figure [6C](#F6){ref-type="fig"}, the specificity of the interaction between His-PmrD and His-PmrA was also demonstrated since the phosphorylation state of His-PmrA could not be detected when incubated with the small cationic proteins RNase A or cytochrome C \[[@B30]\]. Similar levels of phospho-PmrB~C276~were observed in the presence or absence of PmrD (Figure [6D](#F6){ref-type="fig"}), suggesting the His-PmrD had no effect on the phorphorylation state of His-PmrB~C276~.

Discussion
==========

Although the amount of CPS produced by Δ*rcsB*mutant was more than twice of that produced by Δ*wza*mutant, no apparent difference between the wild type strain CG43S3, Δ*wza*mutant, and Δ*rcsB*mutant in polymyxin B resistance could be observed. This is different from the previous finding that *K. pneumoniae*CPS was an important physical barrier for the APs \[[@B10]\]. This discrepancy may be attributed to some of the *K. pneumoniae*strains used for comparison in the previous study produced extremely low level of the CPS. Nevertheless, a higher amount of CPS was protective for the bacterial resistance to polymyxin B.

On the other hand, the deletion of *ugd*resulted in the loss of resistance to polymyxin B. Sequence analysis of the available *K. pneumoniae*genome NTHU-K2044 \[[@B42]\], MGH78578 (http://genome.wustl.edu/) and 342 \[[@B43]\] revealed no PmrA \[[@B17]\] or PhoP box \[[@B27]\] in the upstream region of the *manC*-*manB*-*ugd*genes \[[@B44]\]. This implies the involvement of a regulatory mechanism different from that for *S. enterica ugd*, which was positively regulated by the three 2CS regulators PhoP, PmrA and RcsB \[[@B45]\].

Consistent with the reported findings \[[@B31]\], deletion of *Klebsiella pmrF*which encodes one of the enzymes required for synthesis and incorporation of aminoarabinose in LPS resulted in decreased resistance to polymyxin B and survival within macrophages. The *pmr*expression has been shown to be directly regulated by PhoP under low magnesium or by PmrA in high ferric ions, or by the connector-mediated pathway reported for *Salmonella*,\[[@B31]\]. Similar to the observations in *E. coli*, *S. enterica*\[[@B25]\], *Yersinia pestis*\[[@B46]\], and *Pseudomonas aeruginosa*\[[@B47]\], a positive regulatory role of PmrA and PhoP in polymyxin B resistance in *K. pneumoniae*was also demonstrated.

The deletion of *phoP*resulted in more drastic effect on the bacterial survival in macrophage than the *pmrA*deletion, implying a different level of control between PhoP and PmrA in *K. pneumoniae*resistance to phagocytosis. During phagocytosis, phagosomal maturation and phagolysosomes formation are accompanied by progressive acidification and acquisition of various hydrolases, reactive oxygen, nitrogen species, and APs \[[@B48]\]. Low pH and low-magnesium have been shown to be able to stimulate expression of the PhoP-activated genes \[[@B40],[@B49]\]. Apart from its microbicidal activity, the APs inside phagosomes has even been reported as an inducing signal for the activation of the PhoP/PhoQ system \[[@B50]\]. The deletion of *pmrF*or *phoP*caused a significant reduction in intramacrophage survival of the bacterial, implying a role of the AP resistance regulation in the bacterial pathogenesis.

Until now, PmrD was only found in *E. coli*, *Shigella flexneri*, *S. enterica*and *K. pneumoniae*. Although PmrD in *Klebsiella*appeared to act in a way similar to the PmrD in *S. enterica*, they share only about 40% sequence identity. The expression of *K. pneumoniae pmrD*was shown to be PhoP-dependent and the regulation was achieved through a direct binding of PhoP to the putative *pmrD*promoter. In addition, the binding of PmrD was shown to efficiently protect the PmrA from dephosphorylation. The *in vivo*interaction between PmrD and PmrA demonstrated using 2-hybrid analysis further supported the presence of the connector-mediated pathway in *K. pneumoniae*.

In summary, involvement of *Klebsiella pmr*in polymyxin B resistance and the regulation for the expression of *pmr*genes were analyzed. The regulatory network for the expression of the *pmr*genes is comprised of 2CS response regulators PhoP and PmrA, and the connector protein PmrD. The demonstration of PmrD in prolonging the phosphorylation state of phosphor-PmrA further confirmed the presence of a connector-mediated pathway in *K. pneumoniae*. The complexity in the control of *pmr*genes expression may provide ecological niches for *K. pneumoniae*in response to a variety of environmental clues; for example, in the process of infection.
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